135 results match your criteria: "Proliferating Pilar Tumor"
Clinical Characteristics and Genomic Profile of Malignant Proliferating Trichilemmal Tumor: A Systematic Review of the Literature.
J Surg Oncol
November 2024
Department of Surgery, MercyOne Medical Center, Des Moines, Iowa, USA.
Malignant proliferating trichilemmal tumors (MPTT) are rare skin lesions arising from the outer sheath of the hair follicle root. Because of their rarity and difficulty in pathologic identification, these skin lesions are often initially misdiagnosed. After a literature review, we found initial clinical or histopathological misdiagnosis has an associated 10.
View Article and Find Full Text PDFDiagnosing Common Benign Skin Tumors.
Am Fam Physician
October 2024
Prisma Health and the University of South Carolina School of Medicine, Greenville.
Article Synopsis
- Distinguishing between benign and potentially malignant skin tumors is crucial in family medicine, and many benign tumors can be diagnosed based on their history, appearance, and growth patterns.
- Procedures like biopsy or excision may be necessary if there's uncertainty about a diagnosis or if the lesion changes rapidly.
- Treatment options vary based on the type of lesion and patient preference, with methods like excision, laser therapy, and cryotherapy commonly used; special considerations are needed for patients with darker skin to minimize risks like hypopigmentation.
Article Synopsis
- A proliferating trichilemmal tumor (PTT) is a rare, benign skin tumor that originates from hair follicle structures, typically appearing as firm, exophytic nodules, mostly found on the scalp.
- These tumors can develop either spontaneously or from existing trichilemmal cysts, with a notable case reported where one appeared on a patient's shoulder after 20 years.
- The preferred treatment is surgical removal, with careful examination of the surrounding tissue to ensure complete excision and ongoing follow-up care for the patient.
Malignant Proliferating Pilar Tumor With Sarcomatous Transformation ("Carcinosarcoma"): Case Report With Molecular Profile.
Am J Dermatopathol
January 2025
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Article Synopsis
- Malignant proliferating pilar tumors (MPPTs) are uncommon skin tumors, and cases with sarcomatous transformation are even rarer, with only four documented prior instances.
- This report details a unique case of MPPT with sarcomatous transformation in a 63-year-old male, incorporating molecular, histological, and immunohistochemical analyses alongside follow-up information.
- Genetic findings revealed specific mutations, including a loss-of-function TP53 mutation in both tumor components and an inactivating CDKN2A mutation specific to the sarcomatous part, with the patient remaining disease-free for two years post-diagnosis.
Hallmarks of pancreatic cancer: spotlight on TAM receptors.
EBioMedicine
September 2024
Department of Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB)-CSIC and Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain; Cancer Research Program, Hospital del Mar Research Institute (HMRI), Unidad Asociada IIBB-CSIC, Barcelona, Spain. Electronic address:
Article Synopsis
- * Key challenges in effectively treating PDAC include late diagnosis, complex genetic mutations, high potential for metastasis, a dense fibrous structure, an immune-suppressing environment, and resistance to existing therapies.
- * Recent research highlights the role of TAM (Tyro3, AXL, MerTK) receptors in PDAC development, suggesting they could serve as potential biomarkers for early diagnosis and targets for new treatments, addressing a critical medical need.
Reprogramming of normal fibroblasts into ovarian cancer-associated fibroblasts via non-vesicular paracrine signaling induces an activated fibroblast phenotype.
Biochim Biophys Acta Mol Cell Res
October 2024
Cancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD 57104, USA; Flow Cytometry Core, Sanford Research, Sioux Falls, SD 57104, USA; Department of Obstetrics and Gynecology, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57105, USA; Department of Surgery, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57105, USA. Electronic address:
Article Synopsis
- Cancer-associated fibroblasts (CAFs) play a crucial role in ovarian cancer progression and drug resistance by altering the extracellular matrix (ECM).
- The study shows that media from ovarian cancer cells can activate normal fibroblasts, leading them to adopt a CAF-like phenotype, enhancing their function and increasing tumor growth.
- Ultimately, this research suggests new strategies for developing targeted therapies against CAFs and ECM-related mechanisms that contribute to chemoresistance in ovarian cancer.
Osteosarcoma cells exhibit functional interactions with stromal cells, fostering a lung microenvironment conducive to the establishment of metastatic tumor cells.
Mol Biol Rep
March 2024
Remodeling Processes and cellular niches laboratory, Instituto de Medicina Traslacional e Ingeniería Biomédica (IMTIB)-CONICET-Hospital Italiano Buenos Aires (HIBA)-Instituto Universitario del Hospital Italiano (IUHI), 4240, C1199ACL, Potosí, CABA, Argentina.
Article Synopsis
- Osteosarcoma (OS) is the most prevalent bone tumor, with about 20% of cases being metastatic at diagnosis, often due to unnoticed metastases.
- Mesenchymal stem cells (MSCs) are shown to migrate towards both non-metastatic and metastatic OS cell secretomes, indicating their role in tumor spread and the progression of metastasis, particularly in the lungs.
- The study highlights the interaction between MSCs and OS cells, driven by specific signaling mechanisms, and suggests that understanding these interactions can aid in developing strategies to manage OS metastasis and improve patient outcomes.
A solitary scalp mass as the presenting feature of clear cell sarcoma of the kidney in a pediatric patient.
Pediatr Dermatol
July 2024
Department of Dermatology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Article Synopsis
- - Clear cell sarcoma of the kidney is a rare type of kidney cancer in children, making up about 2%-4% of pediatric kidney tumors.
- - A case study discusses a 9-year-old boy with a seemingly harmless scalp mass that turned out to be metastatic clear cell sarcoma of the kidney.
- - The report emphasizes the importance of imaging scalp masses to ensure correct diagnosis and effective treatment strategies.
Benign proliferating pilar tumor excised with Slow Mohs surgery: A case report.
SAGE Open Med Case Rep
November 2023
Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Saint John, NB, Canada.
Proliferating pilar tumors are rare, benign, exophytic neoplasms, which can closely resemble a squamous cell carcinoma. We describe a patient with a large benign exophytic tumor on the scalp that had been slowly growing over 10 years. While this class of benign follicular tumors is rare, the standard of care is typically excision with clear histologic margins.
View Article and Find Full Text PDFEpidermoid Cyst: An Esthetic Challenge, If Neglected-A Comprehensive Analysis of 217 Cases.
J Cutan Aesthet Surg
January 2023
Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India.
Article Synopsis
- An epidermoid cyst is a benign, keratin-filled growth typically found on the face, scalp, neck, and trunk, but comprehensive studies on them in English literature are limited.
- A retrospective study analyzed 217 cases of epidermoid cysts over 3.6 years, highlighting that they are more common in adults and primarily located in the head and neck, with few cases in rare sites like the breast and tonsils.
- Fine-needle aspiration is an effective diagnostic tool for these cysts, particularly in remote areas, and early diagnosis is crucial to prevent complications like rupture and the need for extensive treatment.
Malignant Proliferating Pilar Tumor: Clinicopathologic, Immunohistochemical, and Molecular Study of 17 Cases.
Am J Surg Pathol
October 2023
Department of Pathology, Massachusetts General Hospital, Harvard Medical School.
Proliferating pilar tumors are rare neoplasms that differentiate toward the outer sheath near the isthmus and can rarely undergo malignant transformation. We performed histopathologic evaluation on 26 benign proliferating pilar tumor (BPPT) and 17 malignant proliferating pilar tumor (MPPT). Ki-67 and p53 immunostains were performed on 13 BPPT and 10 MPPT.
View Article and Find Full Text PDFProliferating Pilar Tumors in the Scalp Over a Period of 23 Years in a General Hospital in Mexico City.
Dermatol Surg
August 2023
National Autonomous University of Mexico, Mexico City, Mexico.
Article Synopsis
- Proliferating pilar tumors are rare skin tumors that typically occur on the scalp, mainly affecting women and originating from hair follicles.
- A study conducted at a hospital in Mexico over 23 years identified 17 cases, with a mean age of 54.9 years; most tumors were benign, though 3 cases were malignant.
- The findings confirm that scalp involvement is common and that while many tumors are asymptomatic and benign, there is a small risk of malignancy that should not be overlooked.
Epidemiology, clinical characteristics, treatment, and outcomes of proliferating pilar tumors: A systematic review.
J Am Acad Dermatol
January 2024
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address:
Article Synopsis
- Proliferating pilar tumors (PPTs) are rare skin tumors linked to hair follicles that can be malignant and metastasize, primarily affecting older women and often located on the scalp.
- A systematic review of 114 articles covering 361 cases showed that the average patient age was 61.7 years, with only a fraction of cases classified for cytological atypia and malignancy, highlighting the need for better reporting practices.
- Current treatment data is inconclusive, but Mohs micrographic surgery has shown some success; however, the overall lack of sufficient varied studies limits definitive conclusions on the best treatment options for PPTs.
Epigenetic reactivation of tumor suppressor genes with CRISPRa technologies as precision therapy for hepatocellular carcinoma.
Clin Epigenetics
April 2023
Cancer Epigenetics Group, The Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, 6009, Australia.
Article Synopsis
- Epigenetic silencing of tumor suppressor genes (TSGs) plays a significant role in the development of hepatocellular carcinoma (HCC), and using CRISPR-activation (CRISPRa) can help reverse this process by targeting these genes directly.
- Analysis of HCC data identified 12 potential TSGs that are silenced due to DNA methylation, and all samples tested had at least one silenced TSG, indicating that a targeted treatment approach could improve patient outcomes.
- The study demonstrates that using a CRISPRa system to reactivate specific TSGs in HCC cells can successfully inhibit cancer-related processes like cell growth and movement, highlighting its potential for personalized therapies.
Local narrow margin excision sequential with modified ALA-PDT for successful treatment of an 86-year-old patient with malignant proliferating trichilemmal tumor.
Photodiagnosis Photodyn Ther
June 2023
Institute of Photomedicine Shanghai Skin Disease Hospital School of Medicine, Tongji University, Shanghai 200443, China; Skin Cancer Center, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China. Electronic address:
Article Synopsis
- Malignant proliferating trichilemmal tumor (MPTT) is a serious form of skin tumor that is linked to benign pilar cysts and arises from the hair root sheath.
- An 86-year-old woman presented with a growth on her skin that was confirmed to be MPTT, but fortunately, it had not spread to other areas.
- After removing the tumor with a careful surgical approach and using a specialized light therapy (ALA-PDT), there were no signs of the tumor returning after two years, highlighting the effectiveness of this combined treatment.
Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.
Sci Rep
February 2023
Instituto de Biología y Medicina Experimental (IBYME-CONICET), Protein Kinases and Cancer Laboratory, ADN1428 CABA, Buenos Aires, Argentina.
Article Synopsis
- Resistance to therapy is a significant challenge in managing cancer, particularly in luminal breast cancer where hormone and CDK4/6 inhibitors often fail.
- This study explored mechanisms of resistance using various cell lines and patient-derived cells, examining how specific kinase inhibitors affect cancer cell survival and aggressiveness.
- The findings suggest that mTOR inhibitors are more effective than PI3K inhibitors in tackling this resistance, and combining mTOR with CDK4/6 inhibitors could enhance treatment outcomes and prevent cancer recurrence.
Proliferating Pilar Tumors Are Characterized by Recurrent 15q, 6q, and 6p22.2 Alterations.
Am J Dermatopathol
April 2023
Department of Pathology, Brigham and Women's Hospital, Boston, MA.
Article Synopsis
- Proliferating pilar tumors (PPTs) are rare tumors usually found on the scalp of older women and can be confused with squamous cell carcinoma (SCC) due to similar characteristics.
- This study utilized advanced DNA sequencing to analyze 5 PPTs and compare them to 5 cutaneous SCCs, revealing specific chromosomal changes in the PPTs that differ from those found in SCCs.
- The findings suggest that PPTs have a unique molecular profile, highlighting alterations in chromosomes 15 and 6 as key to their development, distinguishing them from cutaneous SCCs which showed mutations in known cancer-related genes.
Proliferating Pilar Tumor of the Cheek Misdiagnosed as Squamous Cell Carcinoma.
Indian J Dermatol
January 2022
Department of Plastic and Reconstructive Surgery, Hanil General Hospital, Seoul, Korea.
Article Synopsis
- - Proliferating pilar tumours, or trichilemmal tumours, are uncommon growths from hair follicle structures that can feel firm to soft and form nodules, sometimes leading to skin issues like ulcers.
- - It's crucial to distinguish these tumours from squamous cell carcinoma due to similar appearances, as demonstrated in a case of an 89-year-old woman misdiagnosed with squamous cell carcinoma but later found to have a low-grade malignant proliferating pilar tumour.
- - The report highlights the rarity and atypical features of these tumours, emphasizing the importance of accurate diagnosis in clinical practice.
Corrigendum: Giant, Bleeding, and Ulcerating Proliferating Trichilemmal Cyst, With Delayed Treatment Due to Coronavirus Outbreak: A Case Report and Review of the Literature.
Front Surg
May 2022
Department of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Roskilde, Denmark.
[This corrects the article DOI: 10.3389/fsurg.2021.
View Article and Find Full Text PDFMalignant proliferating trichilemmal tumor of the scalp: report of 4 cases and a short review of the literature.
Case Reports Plast Surg Hand Surg
May 2022
Department of Pathology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.
Article Synopsis
- - Malignant proliferating pilar tumors are uncommon skin lesions that can be mistaken for other types of skin growths.
- - The study discusses four patients who had these tumors on their scalp.
- - A literature review was conducted to explore information and treatment options for malignant proliferating pilar tumors.
Malignant proliferating trichilemmal tumors arising in patients with multiple trichilemmal cysts: A case series.
JAAD Case Rep
April 2022
Department of Dermatology, Centre Hospitalier Universitaire de Québec, Université Laval, Québec, Canada.
The effects of sulfated hyaluronan in breast, lung and colorectal carcinoma and monocytes/macrophages cells: Its role in angiogenesis and tumor progression.
IUBMB Life
October 2022
Laboratorio de Microambiente Tumoral, CIBA, UNNOBA/CIT NOBA (UNNOBA-UNSADA-CONICET), Jorge Newbery 261, Junín, Argentina.
Article Synopsis
- Hyaluronan (HA) is a key part of the extracellular matrix that influences cell behavior in both healthy tissues and tumors, while sulfated hyaluronan (sHA) is a chemically modified version with potential antitumor properties.
- In this study, researchers tested sHA's effects on breast, lung, and colorectal cancer cells, finding that a specific version of sHA (sHA3) reduced cell viability and tumor sizes in breast and lung cancers but had no impact on colorectal cancer cells.
- The results also indicated that sHA3 affected cells in the tumor microenvironment, reducing the expression of angiogenic factors in monocytes/macrophages and decreasing endothelial cell migration, suggesting it could inhibit tumor blood vessel
Polylobulated Scalp Nodule with Heterogeneous Cystic Ultrasound Signs.
Skin Appendage Disord
January 2022
Department of Pathology, Hospital Universitario Príncipe de Asturias, University of Alcalá, Madrid, Spain.